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AbStrACt
introduction: Acute kidney injury (AKI) in hospitalized patients infected with COVID-19 is associated with an 
elevated mortality rate compared to non-infected patients (39% versus 24%). This is despite a lower prevalence of 
AKI in COVID-19-infected patients (17 vs 22%). The reasons are multifactorial and have been well documented in 
developed countries, whereas in developing countries there are scant data. 
Methods: This study aimed to document the mortality in COVID-19-infected South African patients who required 
dialysis for AKI. Exclusion criteria included any chronic kidney replacement therapy (transplantation or dialysis). A 
REDCap survey of South African nephrologists and nephrology fellows registered with the South African Nephrology 
Society was conducted. The primary outcome was all-cause in-hospital mortality, while additional points of interest 
included comorbidities, dialysis modality and intervention required. Univariate analysis of mortality predictors was 
performed.
results: The COVID-19-related AKI mortality rate was 58.9%. Significant predictors included continuous veno-
venous haemodialysis therapy, invasive ventilation, use of inotropes and the presence of shock.  Ischaemic heart 
disease, heart failure and admission to a private healthcare facility were associated with lower mortality. No significant 
associations were found with ethnicity, sex, hypertension, diabetes, HIV infection or the use of other modes of 
dialysis. 
conclusions: In South African patients, we report similar outcomes in critically ill patients requiring dialysis for AKI, 
relative to international data. The predictors of mortality most likely reflect the severity of the illness in our patients. 
The data suggest that continuous veno-venous haemodiafiltration or slow low efficiency dialysis may be the preferred 
dialysis modalities in these patients. 
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INtrODUCtION
Acute kidney injury (AKI) is a common complication of 
COVID-19 infection, with 17% of hospitalized patients 
developing the condition. While the majority of AKI 
episodes appear minor (~50% of AKI is at stage 1), its 
presence can increase the patient’s mortality risk 15-fold 
or more [1-3]. Surprisingly, the incidence of COVID-19-
related AKI (17%) is lower than the documented inci-
dence of pre-COVID-19 AKI of 22% [4]. This contrasts 
with the mortality rate, where the AKI-related mortality 
pre-COVID-19 was 24%, whereas COVID-19 AKI-
related mortality is 39%, and increased to 53% for 
patients requiring continuous renal replacement therapy 
or ICU admission [2,4]. 
The aetiology of AKI associated with COVID-19 infection 
is complex, with multiple mechanisms thought to explain 
the renal injury seen. First, direct toxicity to the kidney is 
postulated, with a direct viral tropism for the kidneys 
noted, especially the proximal tubular cells and podo-
cytes [5,6]. This is compounded by the cytokine release 
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syndrome (CRS), resulting in both intrarenal inflamma-
tion and endothelial dysfunction, aggravating any existing 
renal injury [6-9]. Second, dysfunction of multiple organ 
systems can predispose to AKI, including type 1 cardiorenal 
syndrome from viral myocarditis, renal medullary hypoxia 
from acute respiratory distress syndrome and pre-renal 
failure from shock (hypovolaemic and septic). Third, the 
presence of a hypercoagulable state in COVID-19 infection 
may cause intrarenal ischaemia, predisposing to AKI [10]. 
Lastly, renal dysfunction can be iatrogenic, resulting from 
nephrotoxic agents or renal compartment syndrome from 
vasopressors, aggressive volume expansion and high peak 
airway pressures. Considering the above, the presence of 
AKI in a COVID-19-infected patient may herald the dys-
function of multiple organ systems. This probably accounts 
for the unusually high mortality seen in patients with 
COVID-19-related AKI.
Data and observations from countries affected early in the 
COVID-19 pandemic pointed to a shortage of healthcare 
resources to manage the increasing number of infected 
patients [11]. In particular, a shortage of ICU beds and a 
lack of capacity for renal replacement therapy were 
exposed in many developed countries [12]. In South Africa, 
a developing country, a utilitarian philosophy (the greatest 
good for the greatest number) was adopted and guide-
lines rationing the use of ICU beds were established [13]. 
Initial evidence underpinning these guidelines, especially in 
relation to AKI, were extrapolated from outcomes of 
earlier coronavirus pandemics, namely SARS and MERS 
[14]. Furthermore, very little evidence is available to guide 
the clinician as to which dialysis modality to adopt for 
COVID-19-infected patients with AKI. Ronco et al. acknow-
ledges this, but advocates for high cut-off membranes 
with continuous veno-venous haemodialysis (CVVHD) to 
increase cytokine removal [6,9]. However, mortality in this 
patient group, even with CVVHD, is still above 50% [2]. 
Considering the above, we conducted a nationwide survey 
of nephrologists in South Africa, in order to define the 
COVID-19-related AKI mortality rate during the first 
COVID-19 wave, and establish which modality of dialysis 
was associated with the best outcomes.
MEtHODS
An anonymous online survey was conducted using a 
REDCap database hosted at the University of Pretoria [15]. 
The survey was distributed to all 142 nephrologists and 
trainee nephrologists registered with the South African 
Nephrology Society during the first COVID-19 wave (May 
to September 2020). All data were entered online by the 
treating nephrologist.
We included COVID-19-infected patients diagnosed with 
AKI, who required dialysis. Patients already on chronic 
kidney replacement therapy were excluded. Demographic 
data, comorbidities, dialysis modality, ventilation and 
inotrope requirements were recorded. The outcome of 
interest was all-cause, in-hospital mortality.
The data were exported from REDCap and analysed using 
SPSS (version 27) and MedCalc (version 19.5.2) [16,17]. 
Categorical data were summarized with frequencies, whereas 
continuous data were summarized with means and stan-
dard deviations. Odds ratios were calculated for the cate-
gorical data, using mortality as the outcome. A P value of 
0.05 or less was considered significant.
Ethical approval for the study was granted by the University 
of Pretoria Human Research Ethics Committee (certificate 
308/2020) and approval was also obtained from the South 
African Nephrology Society.
rESULtS
At the completion of the study, 142 responses were 
received. Of these, 52 (37%) were not considered due to 
incomplete data or inadequate informed consent, resulting 
in 90 responses (63%) being available for analysis. All 
patients were diagnosed with COVID-19 infection and 
were in hospital. Although all patients were hospitalized, 
their level of care was not documented. Table 1 summarizes 
the patient characteristics. Of the 90 responses analysed, 
45 (50%) were from the private sector, representing 20 
hospitals, compared to 45 (50%) responses from the public 
sector, representing three hospitals. Of the 90 responses 
received, 78 (87%) were obtained from two provinces 
(Gauteng and Western Cape). Our data revealed a crude 
mortality rate of 58.9%, with a rate of 68.8% in females and 
53.5% in males. Black patients represented the majority of 
the data (61%), followed by Whites (18%). 
The univariable analysis of the association of potential risk 
factors with mortality is summarized in Table 2. Mortality 
was significantly increased in patients who received in-
otropes (odds ratio (OR) 5.32), were diagnosed with shock 
(OR 4.29), required ventilation (OR 6.90) or who resided 
in the Western Cape (OR 3.17). Patients receiving care in 
the private sector had a lower mortality rate (OR 0.37). 
Regarding the different dialysis modalities, the use of inter-
mittent haemodialysis was protective (OR 0.13), slow low 
efficiency dialysis (SLED) and continuous veno-venous 
haemodiafiltration (CVVHDF) had a neutral effect, and 
CVVHD was associated with higher mortality (OR 19.1). 
Among the comorbidities, there were no significant asso-
ciations except for ischaemic heart disease (IHD) (OR 
0.12) and heart failure (OR 0.15), which were associated 
with lower mortality. 
cOViD-19-related acute kidney injury in South african patients
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DISCUSSION
This study assessed the outcomes of AKI in hospitalized 
South Africans infected with COVID-19 during the first 
wave of these infections, and to identify risk factors for 
their mortality. During this period (May to September 
2020), the National Institute for Communicable Diseases 
recorded 259,834 cases of COVID-19 infections in South 
Africa [18]. Conducted over the same period, our study 
reported a mortality rate of 58.9%, which was not signi-
ficantly different from other, international COVID-19 ICU 
mortality data (53%) but was significantly higher than 
mortality reported in other in-hospital studies (39%). This 
suggests that the patients observed in our study had a 
higher burden of disease and most likely required intensive 
care. This is corroborated by the high requirement for 
dialysis (83%), ventilation (63%) and inotropes (53%). 
Interestingly, continuous dialysis modalities were used 
more commonly than the prevalence of shock (48% vs 
38%, respectively). The reason for this is unclear, but may 
represent attempts by the treating nephrologists to 
cOViD-19-related acute kidney injury in South african patients
table 1.  Socio-demographic characteristics of the participants (n = 96). 
Died
Yes (%) no (%) total
total 53 (58.9) 37 (41.1) 90
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Abbreviations: SD, standard deviation; HIV+, patient infected with the human immunodeficiency virus; COPD, chronic obstructive pulmonary disease; ARDS, acute respiratory 
distress syndrome; DIC, disseminated intravascular coagulopathy; HD, haemodialysis; SLED, slow low efficiency dialysis; CVVHD, continuous veno-venous haemodialysis; 
CVVHDF, continuous veno-venous haemodiafiltration.
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increase the clearance of the inflammatory cytokines seen 
during the COVID-19 CRS [6].
The significant predictors of mortality–shock, mechanical 
ventilation, continuous dialysis therapies or inotropes–in 
this study most likely represent the critical illness suffered 
by these patients. However, as COVID-19-related AKI 
likely heralds the dysfunction of multiple organ systems, the 
presence of AKI in an otherwise stable COVID-19-infected 
patient should prompt the clinician to initiate aggressive 
therapy sooner rather than later. This approach can be 
justified by the fact that mortality increases 15-fold in 
COVID-19-infected patients with AKI [1].
A surprising finding from our study was that intermittent 
haemodialysis was a significant predictor of patient survival. 
The current opinion that continuous high cut-off dialytic 
therapies are superior due to increased clearance of 
COVID-19 CRS inflammatory cytokines goes against this 
[6,9]. The theoretical benefit of high cut-off continuous 
therapies, however, may not be the only reason they are 
used in the South African setting; rather, continuous 
therapies may be used in haemodynamically unstable 
patients, whereas intermittent therapies are used for stable 
patients. We suspect that this may have occurred in our 
study, and thus introduced a bias favouring intermittent 
haemodialysis. However, the possibility of high cut-off 
dialytic therapies being beneficial in COVID-19 AKI is still 
appealing. On further analysis of our data, we found that 
CVVHDF had a neutral mortality effect, whereas CVVHD 
was the greatest mortality predictor. This suggests that 
CVVHDF may be the better choice of dialysis in critically ill 
COVID-19 patients, presumably due to removal of CRS 
cytokines. Overall, we noted a protective effect with 
intermittent haemodialysis, a neutral effect with SLED and 
CVVHDF, and a significant increase in mortality with 
CVVHD. Our data suggest that the treating nephrologist 
should take a pragmatic approach, opting for CVVHDF or 
SLED (but not CVVHD) in clinically unstable patients or 
those diagnosed with severe CRS, while intermittent 
therapies are reserved for stable patients with mild to 
moderate COVID-19 infection with no CRS. 
Our finding that IHD and heart failure are significant 
protective factors against mortality is difficult to explain, 
cOViD-19-related acute kidney injury in South african patients
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50
especially as cardiovascular disease is considered a mor-
tality risk factor for COVID-19 infection [9,20]. While the 
small sample size and incomplete responses likely played a 
role, we also suspect underreporting in our study, especially 
regarding IHD, as the prevalence in this study was 12%, 
whereas other studies report IHD at 20–25% [19].
An important finding of this study is that COVID-19-related 
AKI mortality in the South African private sector is 
significantly lower than that of the public (state) sector (OR 
0.37, P = 0.02). A major contributor to this is that South 
Africa’s public sector is markedly under-resourced, having 
limited dialysis services available, and with poor access to 
the more expensive dialysis modalities such as CVVHDF 
[20]. We hope that the introduction of the National Health 
Insurance scheme by the South African government will 
begin to address this issue [21].
This study was limited by a number of factors. The study 
design was an anonymous online survey, which did not 
allow us to determine the response rate, and thus we 
cannot fully assess the representativeness of our samples. 
We suspect underreporting, based on the number of 
responses received. Additionally, there was no represen-
tation from three of the nine provinces in South Africa. 
Another limitation was that we targeted only nephrol-
ogists, and only severe AKI was reported in this survey. 
Lastly, we were unable to report on the cross-over of 
patients to intermittent haemodialysis; many who survived 
CRRT were likely to be converted to intermittent haemo-
dialysis as their condition stabilised. 
In conclusion, our study reports the outcomes of AKI in 
patients with COVID-19 infection in South Africa. We 
found that COVID-19-related AKI has a similar outcome in 
South Africa as in other countries. Our data support the 
use of CVVHDF over CVVHD, but this must be tempered 
by the availability and cost of these modalities. Of note, 
SLED was equivalent to CVVHDF. Lastly, while the data 
suggest that intermittent haemodialysis is protective, this is 
likely due to nephrologists opting to use this modality in the 
less ill, haemodynamically stable patients.
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